ArticleJournal of assisted reproduction and genetics2025
Screening of triploid in miscarriage tissues using medium-coverage whole genome sequencing with a three-algorithm integrated approach.
Article in Journal of assisted reproduction and genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
purposeThis study evaluated the effectiveness and accuracy of medium-coverage whole genome sequencing (CMA-seq) for detecting triploidy in early pregnancy miscarriage tissues, comparing its performance with that of chromosomal microarray analysis (CMA) and low-coverage whole genome sequencing (CNV-seq) combined with short tandem repeat (STR) testing.
methodsIn the initial phase, the CMA-seq analytical framework was validated using four triploid miscarriage samples pre-characterized by standard methods. Three complementary algorithms were applied in parallel: X/Y chromosome dosage ratio analysis to assess read-depth-derived chromosome ratios, SNP-based variant allele frequency (VAF) modeling to differentiate triploid from diploid profiles, and CNV segmentation pattern recognition to identify fractional copy number states relative to a diploid baseline. In the subsequent phase, the validated CMA-seq pipeline was applied to 38 miscarriage tissue samples previously characterized by either CMA (n = 23) or CNV-seq combined with STR testing (n = 15).
resultsDuring validation, X/Y dosage analysis demonstrated an autosome:X:Y ratio of approximately 3:2:1 in male triploid samples and a 2:2 ratio in 69,XXX samples. The SNP-based approach produced distinct VAF profiles characterized by broader curves and higher curvature coefficients in triploid samples, while CNV segmentation Yly identified fractional copy number states (approximately 1.33, 2.67, and 3.33). In clinical evaluation, CMA-seq exhibited complete concordance with CMA results in 23 samples, yielding triploid subtype distributions of 43.5% 69,XXY, 47.8% 69,XXX, and 4.3% 69,XYY (excluding one case due to low DNA concentration), and achieved 100% agreement with CNV-seq combined with STR testing in 15 samples (46.7% 69,XXY and 53.3% 69,XXX).
conclusionsCMA-seq, integrated with a comprehensive algorithmic framework, represents a robust and sensitive approach for detecting triploidy in early pregnancy miscarriage tissues. The method provides detailed genomic profiles that may enhance clinical decision-making and genetic counseling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.